Search Blog
June 2018


NTVA: SEC Declares Intiva BioPharma’s Registration Statement Effective


By Intiva BioPharma Inc.

The Company’s Public Float Increases By 2,463,466 Shares

DENVER, CO / ACCESSWIRE / June 27, 2018 / INTIVA BioPharma Inc. (“INTIVA” or the “Company”) (OTC PINK: NTVA) announced that the United States Securities and Exchange Commission (“SEC”) today declared the Company’s S-1 registration statement effective.

The registration statement registered 2,463,466 shares held by INTIVA investors for resale. The Company has a total of 43,880,896 shares outstanding.

Alain Bankier, INITVA BioPharma’s Interim Chief Executive Officer stated, “Having a liquid trading market for INTIVA’s shares is very important for the Company’s directors and management. We view the SEC’s declaration of effectiveness of the registration statement as a significant step in developing an actively traded market for the Company’s shares.”

About INTIVA BioPharma Inc.

INTIVA BioPharma is a researcher and developer of cannabinoid-based pharmaceuticals in accordance with U.S. Food and Drug Administration (“FDA”) pre-clinical and clinical pathways.

INTIVA BioPharma’s drug development strategy consists of:

The determination of medical conditions and disorders that could potentially benefit from cannabinoid-based formulations;

Conducting “freedom to operate” investigations on these conditions;

The preparation of patent applications and the prosecution of such application and/or the licensing of existing patents;

Identifying the regulatory pathway with the FDA; and

Proceeding with pre-clinical and clinical development activities in accordance with FDA protocols for submission to obtain approval for the particular drug candidate.

INTIVA BioPharma website:

INTIVA Disclosure Notice: This press release contains “forward-looking statements”. For this purpose, any statements contained herein or which are otherwise made by or on behalf of INTIVA BioPharma that are not statements of historical facts may be deemed forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “to,” “plan,” “expect,” “believe,” “anticipate,” “intend,” “could,” “should,” “would,” “estimate,” or “continue,” or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements. Readers are cautioned that all forward-looking statements involve risk and uncertainties which may cause results to differ materially from those set forth in the statements. Such risks and uncertainties include, but are not limited to the following: the success of research and development activities and the speed with which regulatory authorizations and product launches may be achieved; government regulation generally; competitive developments; the ability to successfully market products domestically and internationally; difficulties or delays in manufacturing or issues relating to manufacturing capacity; commercial obstacles to the successful introduction of brand products generally; legal defense costs, insurance expenses, settlement costs, and the risk of an adverse decision or settlement relating to product liability, patent protection, governmental investigations, and other legal proceedings; INTIVA BioPharma’s ability to acquire and protect patents and other intellectual property both domestically and internationally; the absence of certainty regarding the receipt of required regulatory approval or the timing or terms of such approvals; any changes in business, political and economic conditions; business interruption due to hurricanes or other events outside of INTIVA BioPharma’s control.

Readers are cautioned not to place reliance on these forward-looking statements, which are valid only as of the date they were made. INTIVA BioPharma undertakes no obligation to update or revise any forward-looking statements to reflect new information or the occurrence of unanticipated events or otherwise, except as expressly required by law.


Mark Lubchenco
Director of Investor Relations
Intiva BioPharma Inc
303 495 7583

SOURCE: Intiva BioPharma Inc.

ReleaseID: 503772